-
1
-
-
0024988359
-
Activation of programmed cell death by anticancer agents: Cisplatin as a model system
-
Activation of programmed cell death by anticancer agents: cisplatin as a model system. Eastman A, Cancer Cell 1990 2 275 280
-
(1990)
Cancer Cell
, vol.2
, pp. 275-280
-
-
Eastman, A.1
-
2
-
-
0026530828
-
The cDNA structure, expression, and chromosomal assignment of the mouse Fas antigen
-
1371136
-
The cDNA structure, expression, and chromosomal assignment of the mouse Fas antigen. Watanabe-Fukunaga R, Brannan CI, Itoh N, Yonehara S, Copeland NG, Jenkins NA, Nagata S, J Immunol 1992 148 1274 9 1371136
-
(1992)
J Immunol
, vol.148
, pp. 1274-1279
-
-
Watanabe-Fukunaga, R.1
Brannan, C.I.2
Itoh, N.3
Yonehara, S.4
Copeland, N.G.5
Jenkins, N.A.6
Nagata, S.7
-
3
-
-
0028671833
-
Fas and Fas ligand: A death factor and its receptor
-
full-text 7532907
-
Fas and Fas ligand: a death factor and its receptor. Nagata S, Adv Immunol 1994 57 129 44 full-text 7532907
-
(1994)
Adv Immunol
, vol.57
, pp. 129-144
-
-
Nagata, S.1
-
4
-
-
0032522848
-
Human pancreatic adenocarcinomas express Fas and Fas ligand yet are resistant to Fas mediated apoptosis
-
9563493
-
Human pancreatic adenocarcinomas express Fas and Fas ligand yet are resistant to Fas mediated apoptosis. Ungefroren H, Voss M, Jansen M, Roeder C, Henne-Bruns D, Kremer B, Kalthoff H, Cancer Res 1998 58 1741 9 9563493
-
(1998)
Cancer Res
, vol.58
, pp. 1741-1749
-
-
Ungefroren, H.1
Voss, M.2
Jansen, M.3
Roeder, C.4
Henne-Bruns, D.5
Kremer, B.6
Kalthoff, H.7
-
5
-
-
0032893304
-
Pancreatic cancer cells can evade immune surveillance via nonfunctional Fas (APO-1/CD95) receptors and aberrant expression of functional Fas ligand
-
9889801
-
Pancreatic cancer cells can evade immune surveillance via nonfunctional Fas (APO-1/CD95) receptors and aberrant expression of functional Fas ligand. Von Bernstorff W, Spanjaard RA, Chan AK, Lockhart DC, Sadanaga N, Wood I, Peiper M, Goedegebuure PS, Eberlein TJ, Surgery 1999 125 73 84 9889801
-
(1999)
Surgery
, vol.125
, pp. 73-84
-
-
Von Bernstorff, W.1
Spanjaard, R.A.2
Chan, A.K.3
Lockhart, D.C.4
Sadanaga, N.5
Wood, I.6
Peiper, M.7
Goedegebuure, P.S.8
Eberlein, T.J.9
-
6
-
-
0030465072
-
NMR structure and mutagenesis of the Fas (APO-1/CD95) death domain
-
10.1038/384638a0 8967952
-
NMR structure and mutagenesis of the Fas (APO-1/CD95) death domain. Huang B, Eberstadt M, Olejniczak ET, Meadows RP, Fesik SW, Nature 1996 384 638 641 10.1038/384638a0 8967952
-
(1996)
Nature
, vol.384
, pp. 638-641
-
-
Huang, B.1
Eberstadt, M.2
Olejniczak, E.T.3
Meadows, R.P.4
Fesik, S.W.5
-
7
-
-
17044444159
-
Regulation of apoptosis through CD95 (APO-I/Fas) receptor-ligand interaction
-
9191126
-
Regulation of apoptosis through CD95 (APO-I/Fas) receptor-ligand interaction. Debatin KM, Beltinger C, Bohler T, Fellenberg J, Friesen C, Fulda S, Herr I, Los M, Scheuerpflug C, Sieverts H, Stahnke K, Biochem Soc Trans 1997 25 405 410 9191126
-
(1997)
Biochem Soc Trans
, vol.25
, pp. 405-410
-
-
Debatin, K.M.1
Beltinger, C.2
Bohler, T.3
Fellenberg, J.4
Friesen, C.5
Fulda, S.6
Herr, I.7
Los, M.8
Scheuerpflug, C.9
Sieverts, H.10
Stahnke, K.11
-
8
-
-
0030762122
-
Cross-resistance of CD95- and drug-induced apoptosis as a consequence of deficient activation of caspases (ICE/ced-3 proteases)
-
9376593
-
Cross-resistance of CD95- and drug-induced apoptosis as a consequence of deficient activation of caspases (ICE/ced-3 proteases). Los M, Herr I, Friesen C, Fulda S, Schulze-Osthoff K, Debatin K-M, Blood 1997 90 3118 3129 9376593
-
(1997)
Blood
, vol.90
, pp. 3118-3129
-
-
Los, M.1
Herr, I.2
Friesen, C.3
Fulda, S.4
Schulze-Osthoff, K.5
Debatin, K.-M.6
-
9
-
-
0029935682
-
Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells
-
10.1038/nm0596-574 8616718
-
Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells. Friesen C, Herr I, Krammer PH, Debatin KM, Nat Med 1996 2 574 7 10.1038/nm0596-574 8616718
-
(1996)
Nat Med
, vol.2
, pp. 574-577
-
-
Friesen, C.1
Herr, I.2
Krammer, P.H.3
Debatin, K.M.4
-
10
-
-
0030966954
-
Sensitization of cancer cells treated with cytotoxic drugs to Fas-mediated cytotoxicity
-
10.1093/jnci/89.11.783 9182976
-
Sensitization of cancer cells treated with cytotoxic drugs to Fas-mediated cytotoxicity. Micheau O, Solary E, Hammann A, Martin F, Dimanche-Boitrel MT, J Natl Cancer Inst 1997 89 783 9 10.1093/jnci/89.11.783 9182976
-
(1997)
J Natl Cancer Inst
, vol.89
, pp. 783-789
-
-
Micheau, O.1
Solary, E.2
Hammann, A.3
Martin, F.4
Dimanche-Boitrel, M.T.5
-
11
-
-
0031743648
-
P53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs
-
10.1084/jem.188.11.2033 9841917
-
p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. Muller M, Wilder S, Bannasch D, Israeli D, Lehlbach K, Li-Weber M, Friedman SL, Galle PR, Stremmel W, Oren M, Krammer PH, J Exp Med 1998 188 2033 45 10.1084/jem.188.11.2033 9841917
-
(1998)
J Exp Med
, vol.188
, pp. 2033-2045
-
-
Muller, M.1
Wilder, S.2
Bannasch, D.3
Israeli, D.4
Lehlbach, K.5
Li-Weber, M.6
Friedman, S.L.7
Galle, P.R.8
Stremmel, W.9
Oren, M.10
Krammer, P.H.11
-
12
-
-
74549205375
-
Cisplatin Enhances Protein Kinase R-Like Endoplasmic Reticulum Kinase- and CD95-Dependent Melanoma Differentiation-Associated Gene-7/Interleukin-24- Induced Killing in Ovarian Carcinoma Cells
-
10.1124/mol.109.061820 19910452
-
Cisplatin Enhances Protein Kinase R-Like Endoplasmic Reticulum Kinase- and CD95-Dependent Melanoma Differentiation-Associated Gene-7/Interleukin-24- Induced Killing in Ovarian Carcinoma Cells. Yacoub Adly, Liu Renyan, Park Margaret A, Hamed Hossein A, Dash Rupesh, Schramm Danielle N, Sarkar Devanand, Dimitriev Igor P, Bell Jessica K, Grant Steven, Farrell Nicholas P, Curiel David T, Fisher Paul B, Dent Paul, Mol Pharmacol 2010 77 298 310 10.1124/mol.109. 061820 19910452
-
(2010)
Mol Pharmacol
, vol.77
, pp. 298-310
-
-
Yacoub, A.1
Liu, R.2
Park, M.A.3
Hamed, H.A.4
Dash, R.5
Schramm, D.N.6
Sarkar, D.7
Dimitriev, I.P.8
Bell, J.K.9
Grant, S.10
Farrell, N.P.11
Curiel, D.T.12
Fisher, P.B.13
Dent, P.14
-
13
-
-
77649262828
-
Redistribution of CD95 into the Lipid Rafts to Treat Cancer Cells?
-
10.2174/157489210789702190 19663773
-
Redistribution of CD95 into the Lipid Rafts to Treat Cancer Cells? Segui Bruno, Legembre Patrick, Recent Patents on Anti-Cancer Drug Discovery 2010 5 22 28 10.2174/157489210789702190 19663773
-
(2010)
Recent Patents on Anti-Cancer Drug Discovery
, vol.5
, pp. 22-28
-
-
Segui, B.1
Legembre, P.2
-
14
-
-
57549090470
-
Is there a role for the Fas-/Fas-Ligand pathway in chemoresistance of human squamous cell carcinomas of the head and neck (SCCHN)?
-
10.1016/j.oraloncology.2008.04.003 18620901
-
Is there a role for the Fas-/Fas-Ligand pathway in chemoresistance of human squamous cell carcinomas of the head and neck (SCCHN)? Sproll Karl Christoph, Ballo Hilmar, Hoffmann Thomas K, Scheckenbach Kathrin, Koldovsky Ursula, Balz Vera, Hafner Dieter, Ramp Uwe, Bier Henning, Oral Oncology 2009 45 69 84 10.1016/j.oraloncology.2008.04.003 18620901
-
(2009)
Oral Oncology
, vol.45
, pp. 69-84
-
-
Sproll, K.C.1
Ballo, H.2
Hoffmann, T.K.3
Scheckenbach, K.4
Koldovsky, U.5
Balz, V.6
Hafner, D.7
Ramp, U.8
Bier, H.9
-
15
-
-
0033190660
-
Chemoimmunosensitization of the T24 human bladder cancer line to Fas-mediated cytotoxicity and apoptosis by cisplatin and 5-fluorouracil
-
10425290
-
Chemoimmunosensitization of the T24 human bladder cancer line to Fas-mediated cytotoxicity and apoptosis by cisplatin and 5-fluorouracil. Mizutani Y, Wu XX, Yoshida O, Shirasaka T, Bonavida B, Oncol Rep 1999 6 979 82 10425290
-
(1999)
Oncol Rep
, vol.6
, pp. 979-982
-
-
Mizutani, Y.1
Wu, X.X.2
Yoshida, O.3
Shirasaka, T.4
Bonavida, B.5
-
16
-
-
0040419494
-
Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53
-
10.1172/JCI119174 9022073
-
Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. Muller M, Strand S, Hug H, Heinemann EM, Walczak H, Hofmann WJ, Stremmel W, Krammer PH, Galle PR, J Clin Invest 1997 99 3 403 13 10.1172/JCI119174 9022073
-
(1997)
J Clin Invest
, vol.99
, Issue.3
, pp. 403-413
-
-
Muller, M.1
Strand, S.2
Hug, H.3
Heinemann, E.M.4
Walczak, H.5
Hofmann, W.J.6
Stremmel, W.7
Krammer, P.H.8
Galle, P.R.9
-
17
-
-
0000693470
-
Construction and propagation of human adenovirus vectors
-
Academic Press, New York
-
Construction and propagation of human adenovirus vectors. Hitt M, Bett AJ, Prevec L, Graham FL, Cell Biology: Laboratory Handbook Academic Press, New York 1994 479 490
-
(1994)
Cell Biology: Laboratory Handbook
, pp. 479-490
-
-
Hitt, M.1
Bett, A.J.2
Prevec, L.3
Graham, F.L.4
-
18
-
-
0036581160
-
Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR
-
10.1093/nar/30.9.e36 11972351
-
Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Pfaffl MW, Horgan GW, Dempfle L, Nucleic Acids Res 2002 30 36 10.1093/nar/30.9.e36 11972351
-
(2002)
Nucleic Acids Res
, vol.30
, pp. 536
-
-
Pfaffl, M.W.1
Horgan, G.W.2
Dempfle, L.3
-
19
-
-
0028224534
-
Cell biological mechanism of multidrug resistance in tumors
-
10.1073/pnas.91.9.3497 7909602
-
Cell biological mechanism of multidrug resistance in tumors. Simon SM, Schindler M, Proc Natl Acad Sci USA 1994 91 3497 3504 10.1073/pnas.91.9.3497 7909602
-
(1994)
Proc Natl Acad Sci USA
, vol.91
, pp. 3497-3504
-
-
Simon, S.M.1
Schindler, M.2
-
20
-
-
0026489326
-
An intrastrand d(GpG) platinum crosslink in duplex M13 DNA is refractory to repair by human cell extracts
-
10.1073/pnas.89.22.10772 1438274
-
An intrastrand d(GpG) platinum crosslink in duplex M13 DNA is refractory to repair by human cell extracts. Szymkowski DE, Yarema K, Essigmann JM, Lippard SJ, Wood RD, Proc Natl Acad Sci USA 1992 89 10772 10776 10.1073/pnas.89.22. 10772 1438274
-
(1992)
Proc Natl Acad Sci USA
, vol.89
, pp. 10772-10776
-
-
Szymkowski, D.E.1
Yarema, K.2
Essigmann, J.M.3
Lippard, S.J.4
Wood, R.D.5
-
21
-
-
0033638733
-
Cellular predictive factors for the drug response of lung cancer
-
11131647
-
Cellular predictive factors for the drug response of lung cancer. Volm M, Rittgen W, Anticancer Res 2000 20 5B 3449 58 11131647
-
(2000)
Anticancer Res
, vol.20
, Issue.5 B
, pp. 3449-3458
-
-
Volm, M.1
Rittgen, W.2
-
22
-
-
16644396277
-
Loss of caspase-8 activation pathway is a possible mechanism for CDDP resistance in human laryngeal squamous cell carcinoma, HEp-2 cells[J]
-
15289875
-
Loss of caspase-8 activation pathway is a possible mechanism for CDDP resistance in human laryngeal squamous cell carcinoma, HEp-2 cells[J]. Toyozumi Y, Arima N, Izumaru S, Kato S, Morimatsu M, Nakashima T, Int J Oncol 2004 25 3 721 728 15289875
-
(2004)
Int J Oncol
, vol.25
, Issue.3
, pp. 721-728
-
-
Toyozumi, Y.1
Arima, N.2
Izumaru, S.3
Kato, S.4
Morimatsu, M.5
Nakashima, T.6
-
23
-
-
0033667302
-
Cisplatin induces fas expression in esophageal cancer cell lines and enhanced cytotoxicity in combination with LAK cells [J]
-
10.1159/000012192 11096347
-
Cisplatin induces fas expression in esophageal cancer cell lines and enhanced cytotoxicity in combination with LAK cells [J]. Matsuzaki I, Suzuki H, Kitamura M, Minamiya Y, Kawai H, Ogawa J, Oncology 2000 59 4 336 343 10.1159/000012192 11096347
-
(2000)
Oncology
, vol.59
, Issue.4
, pp. 336-343
-
-
Matsuzaki, I.1
Suzuki, H.2
Kitamura, M.3
Minamiya, Y.4
Kawai, H.5
Ogawa, J.6
-
24
-
-
0037049879
-
Induction of apoptosis by cisplatin and its effect on cell cycle-related proteins and cell cycle changes in hepatoma cells
-
10.1016/S0304-3835(01)00720-0 11734333
-
Induction of apoptosis by cisplatin and its effect on cell cycle-related proteins and cell cycle changes in hepatoma cells. Qin LF, Ng IO, Cancer Letters 2002 175 27 38 10.1016/S0304-3835(01)00720-0 11734333
-
(2002)
Cancer Letters
, vol.175
, pp. 27-38
-
-
Qin, L.F.1
Ng, I.O.2
-
25
-
-
0030762122
-
Cross-resistance of CD95- and drug-induced apoptosis as a consequence of deficient activation of caspases (ICE/ced-3 proteases)
-
9376593
-
Cross-resistance of CD95- and drug-induced apoptosis as a consequence of deficient activation of caspases (ICE/ced-3 proteases). Los M, Herr I, Friesen C, Fulda S, Schulze-Osthoff K, Debatin K-M, Blood 1997 90 3118 3129 9376593
-
(1997)
Blood
, vol.90
, pp. 3118-3129
-
-
Los, M.1
Herr, I.2
Friesen, C.3
Fulda, S.4
Schulze-Osthoff, K.5
Debatin, K.-M.6
-
26
-
-
0030064573
-
Insights into mechanisms of cisplatin resistance and potential for its clinical reversal
-
8700790
-
Insights into mechanisms of cisplatin resistance and potential for its clinical reversal. Gosland M, Lum B, Schimmelpfennig J, Baker J, Doukas M, Pharmacotherapy 1996 16 16 39 8700790
-
(1996)
Pharmacotherapy
, vol.16
, pp. 16-39
-
-
Gosland, M.1
Lum, B.2
Schimmelpfennig, J.3
Baker, J.4
Doukas, M.5
-
27
-
-
0026737805
-
Increased gene-specific repair of cisplatin interstrand cross-links in cisplatin-resistant human ovarian cancer cell lines
-
1380646
-
Increased gene-specific repair of cisplatin interstrand cross-links in cisplatin-resistant human ovarian cancer cell lines. Zhen W, Link CJ Jr, O'Connor PM, Reed E, Parker R, Howell SB, Bohr VA, Mol Cell Biol 1992 12 3689 98 1380646
-
(1992)
Mol Cell Biol
, vol.12
, pp. 3689-3698
-
-
Zhen, W.1
Link Jr., C.J.2
O'Connor, P.M.3
Reed, E.4
Parker, R.5
Howell, S.B.6
Bohr, V.A.7
-
28
-
-
0031791029
-
Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy
-
10.1016/S0305-7372(98)90056-1 9861196
-
Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. Reed E, Cancer Treat Rev 1998 24 331 44 10.1016/S0305-7372(98)90056-1 9861196
-
(1998)
Cancer Treat Rev
, vol.24
, pp. 331-344
-
-
Reed, E.1
-
29
-
-
0028141961
-
Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy
-
10.1172/JCI117388 8040325
-
Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. Dabholkar M, Vionnet J, Bostick-Bruton F, Yu JJ, Reed E, J Clin Invest 1994 94 703 8 10.1172/JCI117388 8040325
-
(1994)
J Clin Invest
, vol.94
, pp. 703-708
-
-
Dabholkar, M.1
Vionnet, J.2
Bostick-Bruton, F.3
Yu, J.J.4
Reed, E.5
-
30
-
-
0034054137
-
Association between the level of ERCC-1 expression and the repair of cisplatin-induced DNA damage in human ovarian cancer cells
-
10810335
-
Association between the level of ERCC-1 expression and the repair of cisplatin-induced DNA damage in human ovarian cancer cells. Li Q, Yu JJ, Mu C, Yunmbam MK, Slavsky D, Cross CL, Bostick-Bruton F, Reed E, Anticancer Res 2000 20 645 652 10810335
-
(2000)
Anticancer Res
, vol.20
, pp. 645-652
-
-
Li, Q.1
Yu, J.J.2
Mu, C.3
Yunmbam, M.K.4
Slavsky, D.5
Cross, C.L.6
Bostick-Bruton, F.7
Reed, E.8
-
31
-
-
33645030839
-
Applications of genomics in NSCLC
-
10.1016/S0169-5002(05)81571-5 16557672
-
Applications of genomics in NSCLC. Rosell R, Cobo M, Isla D, Sanchez JM, Taron M, Altavilla G, Santarpia M, Moran T, Catot S, Etxaniz O, Lung Cancer 2005 50 Suppl 2 33 40 10.1016/S0169-5002(05)81571-5 16557672
-
(2005)
Lung Cancer
, vol.50
, Issue.SUPPL. 2
, pp. 1933-1940
-
-
Rosell, R.1
Cobo, M.2
Isla, D.3
Sanchez, J.M.4
Taron, M.5
Altavilla, G.6
Santarpia, M.7
Moran, T.8
Catot, S.9
Etxaniz, O.10
-
32
-
-
16644373622
-
Correlation analysis among expression of ERCC-1, metallothionein, p53 and platinum resistance and prognosis in advanced non-small cell lung cancer
-
15248926
-
Correlation analysis among expression of ERCC-1, metallothionein, p53 and platinum resistance and prognosis in advanced non-small cell lung cancer. Huang PY, Liang XM, Lin SX, Luo RZ, Hou JH, Zhang L, Ai Zheng 2004 23 845 50 15248926
-
(2004)
Ai Zheng
, vol.23
, pp. 845-850
-
-
Huang, P.Y.1
Liang, X.M.2
Lin, S.X.3
Luo, R.Z.4
Hou, J.H.5
Zhang, L.6
-
33
-
-
0041766793
-
Nucleotide excision repair pathways involved in Cisplatin resistance in non-small-cell lung cancer
-
12915808
-
Nucleotide excision repair pathways involved in Cisplatin resistance in non-small-cell lung cancer. Rosell R, Taron M, Barnadas A, Scagliotti G, Sarries C, Roig B, Cancer Control 2003 10 297 305 12915808
-
(2003)
Cancer Control
, vol.10
, pp. 297-305
-
-
Rosell, R.1
Taron, M.2
Barnadas, A.3
Scagliotti, G.4
Sarries, C.5
Roig, B.6
-
34
-
-
2442419814
-
Reduced levels of XPA, ERCC1 and XPF DNA repair proteins in testis tumor cell lines
-
10.1002/ijc.20134 15095299
-
Reduced levels of XPA, ERCC1 and XPF DNA repair proteins in testis tumor cell lines. Welsh C, Day R, McGurk C, Masters JRW, Wood RD, Köberle B, Int J Cancer 2004 110 352 361 10.1002/ijc.20134 15095299
-
(2004)
Int J Cancer
, vol.110
, pp. 352-361
-
-
Welsh, C.1
Day, R.2
McGurk, C.3
Masters, J.R.W.4
Wood, R.D.5
Köberle, B.6
-
35
-
-
11144241323
-
Small interfering RNAinduced suppression of ERCC1 enhances sensitivity of human cancer cells to cisplatin
-
10.1016/j.bbrc.2004.12.008 15629453
-
Small interfering RNAinduced suppression of ERCC1 enhances sensitivity of human cancer cells to cisplatin. Chang IY, Kim MH, Kim HB, Lee DY, Kim SH, Kim HY, You HJ, Biochem Biophys Res Commun 2005 327 225 233 10.1016/j.bbrc.2004.12. 008 15629453
-
(2005)
Biochem Biophys Res Commun
, vol.327
, pp. 225-233
-
-
Chang, I.Y.1
Kim, M.H.2
Kim, H.B.3
Lee, D.Y.4
Kim, S.H.5
Kim, H.Y.6
You, H.J.7
-
36
-
-
0345256652
-
Cisplatin: Mode of cytotoxic action and molecular basis of resistance
-
10.1038/sj.onc.1206933 14576837
-
Cisplatin: mode of cytotoxic action and molecular basis of resistance. Siddik ZH, Oncogene 2003 22 7265 79 10.1038/sj.onc.1206933 14576837
-
(2003)
Oncogene
, vol.22
, pp. 7265-7279
-
-
Siddik, Z.H.1
-
37
-
-
24744452853
-
Augmented expression of metallothionein and glutathione S-transferase pi as unfavourable prognostic factors in cisplatin-treated ovarian cancer patients
-
10.1007/s00428-005-1228-0 15968547
-
Augmented expression of metallothionein and glutathione S-transferase pi as unfavourable prognostic factors in cisplatin-treated ovarian cancer patients. Surowiak P, Materna V, Kaplenko I, Marek S, Dietel M, Lage H, Zabel M, Virchows Arch 2005 447 626 33 10.1007/s00428-005-1228-0 15968547
-
(2005)
Virchows Arch
, vol.447
, pp. 626-633
-
-
Surowiak, P.1
Materna, V.2
Kaplenko, I.3
Marek, S.4
Dietel, M.5
Lage, H.6
Zabel, M.7
-
38
-
-
16644389605
-
The relationship of the human glutathione S-transferase PI polymorphism and chemotherapeutic sensitivity in head and neck squamous carcinoma
-
15254763
-
The relationship of the human glutathione S-transferase PI polymorphism and chemotherapeutic sensitivity in head and neck squamous carcinoma. Kimura S, Imagawa Y, Satake K, Tsukuda M, Int J Mol Med 2004 14 185 9 15254763
-
(2004)
Int J Mol Med
, vol.14
, pp. 185-189
-
-
Kimura, S.1
Imagawa, Y.2
Satake, K.3
Tsukuda, M.4
-
39
-
-
0346365372
-
Glutathione S-transferase pi amplification is associated with cisplatin resistance in head and neck squamous cell carcinoma cell lines and primary tumors
-
14678959
-
Glutathione S-transferase pi amplification is associated with cisplatin resistance in head and neck squamous cell carcinoma cell lines and primary tumors. Cullen KJ, Newkirk KA, Schumaker LM, Aldosari N, Rone JD, Haddad BR, Cancer Res 2003 63 8097 102 14678959
-
(2003)
Cancer Res
, vol.63
, pp. 8097-8102
-
-
Cullen, K.J.1
Newkirk, K.A.2
Schumaker, L.M.3
Aldosari, N.4
Rone, J.D.5
Haddad, B.R.6
-
40
-
-
0032436607
-
Glutathione S-transferase pi immunostaining of cisplatin-resistant ovarian cancer cells in ascites
-
9850649
-
Glutathione S-transferase pi immunostaining of cisplatin-resistant ovarian cancer cells in ascites. Kase H, Kodama S, Nagai E, Tanaka K, Acta Cytol 1998 42 1397 402 9850649
-
(1998)
Acta Cytol
, vol.42
, pp. 1397-1402
-
-
Kase, H.1
Kodama, S.2
Nagai, E.3
Tanaka, K.4
-
41
-
-
0035452367
-
Glutathioneassociated enzymes in head and neck squamous cell carcinoma and response to cisplatin-based neoadjuvant chemotherapy
-
10.1002/ijc.1392 11477586
-
Glutathioneassociated enzymes in head and neck squamous cell carcinoma and response to cisplatin-based neoadjuvant chemotherapy. Cabelguenne A, Loriot MA, Stucker I, Blons H, Koum-Besson E, Brasnu D, Beaune P, Laccourreye O, Laurent-Puig P, Waziers ID, Int J Cancer 2001 93 725 30 10.1002/ijc.1392 11477586
-
(2001)
Int J Cancer
, vol.93
, pp. 725-730
-
-
Cabelguenne, A.1
Loriot, M.A.2
Stucker, I.3
Blons, H.4
Koum-Besson, E.5
Brasnu, D.6
Beaune, P.7
Laccourreye, O.8
Laurent-Puig, P.9
Waziers, I.D.10
|